Datopotamab Deruxtecan Nearly Doubles Survival in Triple-Negative Breast Cancer Trial

The global phase III TROPION-Breast02 trial, led by the National Cancer Centre Singapore, demonstrates that datopotamab deruxtecan (Dato-DXd), a novel antibody-drug conjugate, significantly improves survival outcomes in patients with untreated, advanced triple-negative breast cancer. The trial findings, published in the Annals of Oncology, show the experimental drug nearly doubles survival for this aggressive cancer type. Triple-negative breast cancer represents a particularly challenging disease with limited treatment options. The multicenter trial results position datopotamab deruxtecan as a potential new standard treatment option, representing a major breakthrough in addressing an unmet medical need for these patients.

TROPION-Breast02 Trial Results and Methodology

• ▪TROPION-Breast02 trial findings were published in the Annals of Oncology.
• ▪TROPION-Breast02 was led by a senior medical oncologist and researcher from the National Cancer Centre Singapore.
• ▪TROPION-Breast02 demonstrated a significant breakthrough in improving survival of patients with untreated, advanced triple negative breast cancer.
• ▪TROPION-Breast02 is a global, multicenter phase III trial.

Datopotamab Deruxtecan as Treatment for Triple-Negative Breast Cancer

• ▪Triple negative breast cancer is described as an aggressive disease.
• ▪Datopotamab deruxtecan is abbreviated as Dato-DXd.
• ▪TROPION-Breast02 trial findings demonstrate the potential of datopotamab deruxtecan as an effective new treatment option for triple negative breast cancer.
• ▪Datopotamab deruxtecan is a novel antibody-drug conjugate.
• ▪Datopotamab deruxtecan was used to treat patients with untreated, advanced triple negative breast cancer in the TROPION-Breast02 trial.

Perspective of National Cancer Centre Singapore researchers

• ▪The TROPION-Breast02 trial addresses an unmet medical need for patients with untreated, advanced triple negative breast cancer.
• ▪Datopotamab deruxtecan represents a major breakthrough for triple-negative breast cancer treatment according to National Cancer Centre Singapore researchers.

Perspective of Triple-negative breast cancer patients

• ▪Triple-negative breast cancer patients previously had limited effective treatment options for advanced disease.
• ▪Datopotamab deruxtecan nearly doubles survival outcomes for triple-negative breast cancer patients compared to standard treatment.

1 source